PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33194590-8	2020	The combination of Birinapant with Ralimetinib, inhibitor of p38alpha, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant.	ralimetinib	35-46	mitogen-activated protein kinase 14	Homo sapiens	61-69
32976869-1	2021	BACKGROUND AND PURPOSE: This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients.	ralimetinib	139-150	mitogen-activated protein kinase 14	Homo sapiens	119-127
32976869-11	2021	CONCLUSION: This phase 1 trial is the first trial to study the combination of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients.	ralimetinib	100-111	mitogen-activated protein kinase 14	Homo sapiens	80-88
33194590-8	2020	The combination of Birinapant with Ralimetinib, inhibitor of p38alpha, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant.	ralimetinib	35-46	serine/threonine kinase 11	Homo sapiens	99-103
33194590-8	2020	The combination of Birinapant with Ralimetinib, inhibitor of p38alpha, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant.	ralimetinib	35-46	KRAS proto-oncogene, GTPase	Homo sapiens	109-113
33194590-8	2020	The combination of Birinapant with Ralimetinib, inhibitor of p38alpha, restores the sensitivity of LKB1- and KRAS-mutated cell lines to the IAP inhibitor Birinapant.	ralimetinib	35-46	magnesium transporter 1	Homo sapiens	140-143
33194590-10	2020	In addition, combination of Birinapant and a KRAS pathway inhibitor, as Ralimetinib, could be useful for patients with LKB1 and KRAS-mutated NSCLC.	ralimetinib	72-83	KRAS proto-oncogene, GTPase	Homo sapiens	45-49
33194590-10	2020	In addition, combination of Birinapant and a KRAS pathway inhibitor, as Ralimetinib, could be useful for patients with LKB1 and KRAS-mutated NSCLC.	ralimetinib	72-83	serine/threonine kinase 11	Homo sapiens	119-123
33194590-10	2020	In addition, combination of Birinapant and a KRAS pathway inhibitor, as Ralimetinib, could be useful for patients with LKB1 and KRAS-mutated NSCLC.	ralimetinib	72-83	KRAS proto-oncogene, GTPase	Homo sapiens	128-132
26581242-2	2016	Ralimetinib (LY2228820 dimesylate) is a selective small-molecule inhibitor of p38 MAPK.	ralimetinib	0-11	mitogen-activated protein kinase 14	Homo sapiens	78-81
31707688-0	2020	A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.	ralimetinib	162-173	mitogen-activated protein kinase 14	Homo sapiens	104-140
31707688-0	2020	A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.	ralimetinib	162-173	mitogen-activated protein kinase 14	Homo sapiens	142-150
31707688-1	2020	Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which may be safely administered to patients with advanced cancer.	ralimetinib	202-213	mitogen-activated protein kinase 14	Homo sapiens	154-190
31791552-9	2020	Grade 3/4 elevated alanine aminotransferase was more common in the ralimetinib arm.	ralimetinib	67-78	glutamic--pyruvic transaminase	Homo sapiens	19-43
26581242-0	2016	A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.	ralimetinib	63-74	mitogen-activated protein kinase 14	Homo sapiens	43-46
31048666-9	2020	Ralimetinib, an oral p38 mitogen-activated protein kinase (MAPK) inhibitor could inhibit CTSC expression.	ralimetinib	0-11	mitogen-activated protein kinase 14	Homo sapiens	21-57
31048666-9	2020	Ralimetinib, an oral p38 mitogen-activated protein kinase (MAPK) inhibitor could inhibit CTSC expression.	ralimetinib	0-11	cathepsin C	Homo sapiens	89-93
27179115-0	2016	Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.	ralimetinib	75-86	mitogen-activated protein kinase 14	Homo sapiens	55-58
26581242-8	2016	After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells.	ralimetinib	21-32	mitogen-activated protein kinase 14	Homo sapiens	43-46
26581242-8	2016	After a single dose, ralimetinib inhibited p38 MAPK-induced phosphorylation of MAPKAP-K2 in peripheral blood mononuclear cells.	ralimetinib	21-32	MAPK activated protein kinase 2	Homo sapiens	79-88
33767160-8	2021	In particular, the p38alpha kinase inhibitor ralimetinib, which has already entered clinical trials, promoted sensitization of patient-derived CRC-SCs to chemotherapeutic agents commonly used for CRC treatment and showed a synthetic lethality effect when used in combination with the MEK1 inhibitor trametinib.	ralimetinib	45-56	mitogen-activated protein kinase 14	Homo sapiens	19-27
33767160-8	2021	In particular, the p38alpha kinase inhibitor ralimetinib, which has already entered clinical trials, promoted sensitization of patient-derived CRC-SCs to chemotherapeutic agents commonly used for CRC treatment and showed a synthetic lethality effect when used in combination with the MEK1 inhibitor trametinib.	ralimetinib	45-56	mitogen-activated protein kinase kinase 1	Homo sapiens	284-288